Merck KGaA (ETR:MRK)
112.65
+1.00 (0.90%)
Jun 27, 2025, 5:35 PM CET
Merck KGaA Employees
Merck KGaA had 59,020 employees as of December 31, 2024. The number of employees decreased by 3,888 or -6.18% compared to the previous year.
Employees
59,020
Change (1Y)
-3,888
Growth (1Y)
-6.18%
Revenue / Employee
€340,489
Profits / Employee
€45,013
Market Cap
47.70B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 59,020 | -3,888 | -6.18% |
Dec 31, 2023 | 62,908 | -1,324 | -2.06% |
Dec 31, 2022 | 64,232 | 3,898 | 6.46% |
Dec 31, 2021 | 60,334 | 2,207 | 3.80% |
Dec 31, 2020 | 58,127 | 1,056 | 1.85% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Related Stocks
Company Name | Employees |
---|---|
Siemens Healthineers AG | 72,000 |
Bayer Aktiengesellschaft | 91,864 |
Fresenius SE & Co. KGaA | 176,486 |
Fresenius Medical Care AG | 111,513 |
Sartorius Aktiengesellschaft | 13,528 |
Carl Zeiss Meditec AG | 5,730 |
Fielmann Group AG | 24,363 |
SCHOTT Pharma AG & Co. KGaA | 4,690 |
Merck KGaA News
- 9 days ago - Merck Foundation Chairman, CEO, and 14 First Ladies Inaugurate the 7th Edition of Merck Foundation First Ladies Initiative – MFFLI Summit in Dubai - Business Upturn
- 10 days ago - MilliporeSigma Announces Neoclease as Winner of 2025 North American Advance Biotech Grant - Financial Post
- 15 days ago - EQS-PVR: Merck KGaA: Correction of a release from 05/06/2025 according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution - Wallstreet:Online
- 18 days ago - China's Center for Drug Evaluation Accepts Merck KGaA, Darmstadt, Germany's Application for Marketing Authorization of Pimicotinib for Treatment of Tenosynovial Giant Cell Tumor - Benzinga
- 18 days ago - China's Center for Drug Evaluation Accepts Merck KGaA, Darmstadt, Germany's Application for Marketing Authorization of Pimicotinib for Treatment of Tenosynovial Giant Cell Tumor - Business Wire
- 18 days ago - China's Center for Drug Evaluation Accepts Merck's Application for Marketing Authorization of Pimicotinib for Treatment of Tenosynovial Giant Cell Tumor - Business Wire
- 23 days ago - EQS-PVR: Merck KGaA: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution - Wallstreet:Online
- 24 days ago - SPRINGWORKS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of SpringWorks Therapeutics, Inc. - SWTX - Wallstreet:Online